Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
NCT ID: NCT02547844
Last Updated: 2017-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2015-09-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera
NCT02447016
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
NCT02652260
SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
NCT02529059
Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers
NCT01796431
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
NCT01108926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
efavirenz + emtricitabina + tenofovir
Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
efavirenz + emtricitabina + tenofovir
rilpivirina + emtricitabina + tenofovir
Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
rilpivirina + emtricitabina + tenofovir
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
efavirenz + emtricitabina + tenofovir
rilpivirina + emtricitabina + tenofovir
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients infected with HIV-1
* Patients treated with Atripla at least the last 6 months.
* Patients with virologic suppression (HIV RNA \<50 copies / ml) for at least the last 6 months.
* Women of childbearing potential must use contraception double barrier.
* Voluntary signature of informed consent
Exclusion Criteria
* Women pregnant or lactating
* Abuse of alcohol or other drugs
* Body Mass Index (BMI)\> 25
* Use of drugs that may affect lipid metabolism (lipid-lowering drugs, steroids ...)
* Patients unable to understand the study protocol or any other condition that in the investigator's opinion could jeopardize compliance with the protocol
* History or presence of allergy to any of the study drugs or their components
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EfaRiLipidomics
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.